|Manufacturer:||The Medicines Company|
Cleviprex was evaluated in a randomized, placebo-controlled, single-blind, parallel 72 hour continuous infusion study in 61 mild to moderate essential hypertensives.
The mean baseline blood pressure was 151/86 mmHg.Subjects were randomized to placebo or to 2, 4, 8, or 16 mg/hour.
Doses above 2 mg/hour were started at 2 mg/hour and force-titrated in 2-fold increments at 3-minute intervals.
Blood pressure, heart rate, and blood levels of clevidipine butyrate were measured during the infusion period.
Blood levels were monitored 1 hour after the infusion was discontinued.
Blood pressure and heart rate were monitored for 8 hours and also at 96 hours after the termination of infusion.
Systolic blood pressure effect was related to the concentration of clevidipine butyrate and plateaued at higher measured concentrations, with the maximal effect estimated at 25% of baseline systolic blood pressure.The estimated infusion rate necessary to achieve half of this maximal effect was approximately 10 mg/hour.